EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, APM: Aptorum Group Ltd Cl A

24 Oct 25 15:59
LAST:

1.490

CHANGE:
 0.01		OPEN:
1.510		HIGH:
1.590		ASK:
0.000		VOLUME:
128.9K
CHG(%):
0.67		PREV:
1.500		LOW:
1.460		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
24 Oct 251.5101.5901.4601.490133.1K
23 Oct 251.4501.5301.4401.500127.6K
22 Oct 251.5901.5901.4001.490238.7K
21 Oct 251.5801.6341.5451.60063.0K
20 Oct 251.5101.6751.5101.600107.5K
17 Oct 251.5001.5881.4701.550102.8K
16 Oct 251.5601.5801.5201.520120.8K
15 Oct 251.5901.6301.5301.570141.2K
14 Oct 251.5601.6001.5001.590201.3K
13 Oct 251.7601.7601.4001.580431.9K

COMPANY PROFILE

Name:Aptorum Group Ltd Cl A
About:Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Sector:Healthcare
Industry:Biotechnology
Address:17 Hanover Square, London, United Kingdom, W1S 1BN
Website:https://www.aptorumgroup.com
CUSIP:G6096M106
CIK:0001734005
ISIN:KYG6096M1069
FIGI:BBG00LX0JFQ4

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:1.543.1%
MA10:1.554.0%
MA20:1.8423.6%
MA50:1.9027.3%
MA100:1.585.8%
MA200:1.2915.8%
RSI14:25.15 
WPR14:-100.00 
MTM14:-0.60
ROC14:-0.29 
ATR:0.24 
Week High:1.6812.4%
Week Low:1.406.4%
Month High:2.5973.8%
Month Low:1.4015.8%
Year High:7.49402.7%
Year Low:0.46223.9%
Volatility:134.40 

RECENT SPLITS

Date Ratio
23 Jan 20231-10